Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the efficacy and safety of sirolimus (oral form), to
decrease the volume and symptoms due to superficial arteriovenous malformations (AVM).
Sirolimus has properties that reduce the activity of the immune system (immunosuppressant),
to fight against the proliferation of cancer cells (anti- tumor) and also reduce the
proliferation of blood vessels (anti -vascular). Sirolimus is primarily used in transplant
patients to prevent organ transplant rejection. Many animal and laboratory studies were
carried out and demonstrate in particular the activity of sirolimus on vessels. It is this
anti- vascular effect that could help treat arteriovenous malformations.